The ‘landmark’ decision invalidates Regeneron’s patent claims covering its genetically modified mice

The drug targets all solid tumours with the NTRK gene fusions

Updated Date: Wed, 17 Jun 2020 00:00:00 EDT

Updated Date: Wed, 17 Jun 2020 00:00:00 EDT

Updated Date: Wed, 17 Jun 2020 00:00:00 EDT

Updated Date: Wed, 17 Jun 2020 00:00:00 EDT

Updated Date: Wed, 17 Jun 2020 00:00:00 EDT

Merck treads on Sanofi, Regeneron’s turf with Keytruda’s latest skin cancer OK chelfand Wed, 06/24/2020 – 16:43

Regeneron vows to fight DOJ lawsuit alleging charity donations were Eylea kickbacks esagonowsky Wed, 06/24/2020 – 16:23

Bayer inks largest settlement in pharma history with $10B Roundup deal kblankenship Wed, 06/24/2020 – 13:49